Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.
MacCarthy EP, Bloomfield SS.
Pharmacotherapy. 1983 Jul-Aug;3(4):193-219. doi: 10.1002/j.1875-9114.1983.tb03252.x.
Raynaud's phenomenon.
Belch JJ.
Curr Opin Rheumatol. 1991 Dec;3(6):960-6. doi: 10.1097/00002281-199112000-00011.
Clinical Puzzles and Decision-Making in Antisynthetase Syndrome.
Yehudina Y, Trypilka S, Isayeva A.
Cureus. 2021 Jun 25;13(6):e15931. doi: 10.7759/cureus.15931.
Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean.
Dorji T, Hegde A, Asturkar V, Yangzom S, Bhanu K.
J Assoc Physicians India. 2022 Apr;70(4):11-12.
Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.
Murdoch D, Brogden RN.
Drugs. 1991 May;41(5):737-79. doi: 10.2165/00003495-199141050-00006.
Raynaud's phenomenon: subjective influence of female sex hormones.
Bartelink ML, Wollersheim H, van de Lisdonk E, Thien T.
Int Angiol. 1992 Oct-Dec;11(4):309-15.
Recognition and treatment of arterial insufficiency from cafergot.
Wells KE, Steed DL, Zajko AB, Webster MW.
J Vasc Surg. 1986 Jul;4(1):8-15.
